Biospecifics Technologies (BSTC) Balance Sheet

Click line-items for a historical chart and %

Cash and cash equivalents	4.75M
Short-term investments	45.08M
Accounts receivable, net	3.85M
Income tax receivable	0
Deferred tax assets
Prepaid expenses and other current assets	554.4K
Total current assets	55.44M
Deferred royalty buy-down	1.91M
Deferred tax assets -long term	3.37M
Patent costs, net
Total assets	62.44M
Accounts payable and accrued expenses
Accrued third-party development expenses
Deferred revenue	1.22M
Accrued liabilities of discontinued operations	78.14K
Total current liabilities	2.57M
Long-term deferred revenue	6.64M
Series A Preferred stock, $.50 par value, 700,000 shares authorized; none outstanding	0
Common stock, $.001 par value; 10,000,000 shares authorized; 6,520,743 and 6,445,743 shares issued at June 30, 2011 and December 31, 2010, respectively	7.55K
Additional paid-in capital	32.65M
Accumulated deficit	27.69M
Treasury stock, 160,652 and 151,875 shares at cost at June 30, 2011 and December 31, 2010, respectively	-7.13M
Total stockholders' equity	53.22M
Total liabilities and stockholders' equity	62.44M

Entities mentioned with BSTC

View All Entities